TY - JOUR
T1 - Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD
AU - Lu, Y.
AU - Kitaura, J.
AU - Oki, T.
AU - Komeno, Y.
AU - Ozaki, K.
AU - Kiyono, M.
AU - Kumagai, H.
AU - Nakajima, H.
AU - Nosaka, T.
AU - Aburatani, H.
AU - Kitamura, T.
N1 - Funding Information:
We thank Dr Hitoshi Kawamata for providing plasmid pEGFP-TSC-22-LZ. We thank Dr Naoko Watanabe, Dr Yoshinori Yamanishi, Dr Kumi Izawa and Dr Yukinori Minoshima for valuable discussions, Fumi Shibata, Miyuki Ito and Ai Hishiya for excellent technical assistance. We also thank R&D Systems for cytokines. This work was supported in part by Grants-in-Aid from the Ministry of Education, Science, Technology, Sports, and Culture in Japan.
PY - 2007/11
Y1 - 2007/11
N2 - Transforming growth factor-β (TGF-β)-stimulated clone-22 (TSC-22) was originally isolated as a TGF-β-inducible gene. In this study, we identified TSC-22 as a potential leukemia suppressor. Two types of FMS-like tyrosine kinase-3 (Flt3) mutations are frequently found in acute myeloid leukemia: Flt3-ITD harboring an internal tandem duplication in the juxtamembrane domain associated with poor prognosis and Flt3-TKD harboring a point mutation in the kinase domain. Comparison of gene expression profiles between Flt3-ITD- and Flt3-TKD-transduced Ba/F3 cells revealed that constitutive activation of Flt3 by Flt3-TKD, but not Flt3-ITD, upregulated the expression of TSC-22. Importantly, treatment with an Flt3 inhibitor PKC412 or an Flt3 small interfering RNA decreased the expression level of TSC-22 in Flt3-TKD-transduced cells. Forced expression of TSC-22 suppressed the growth and accelerated the differentiation of several leukemia cell lines into monocytes, in particular, in combination with differentiation-inducing reagents. On the other hand, a dominant-negative form of TSC-22 accelerated the growth of Flt3-TKD-transduced 32Dcl.3 cells. Collectively, these results suggest that TSC-22 is a possible target of leukemia therapy.
AB - Transforming growth factor-β (TGF-β)-stimulated clone-22 (TSC-22) was originally isolated as a TGF-β-inducible gene. In this study, we identified TSC-22 as a potential leukemia suppressor. Two types of FMS-like tyrosine kinase-3 (Flt3) mutations are frequently found in acute myeloid leukemia: Flt3-ITD harboring an internal tandem duplication in the juxtamembrane domain associated with poor prognosis and Flt3-TKD harboring a point mutation in the kinase domain. Comparison of gene expression profiles between Flt3-ITD- and Flt3-TKD-transduced Ba/F3 cells revealed that constitutive activation of Flt3 by Flt3-TKD, but not Flt3-ITD, upregulated the expression of TSC-22. Importantly, treatment with an Flt3 inhibitor PKC412 or an Flt3 small interfering RNA decreased the expression level of TSC-22 in Flt3-TKD-transduced cells. Forced expression of TSC-22 suppressed the growth and accelerated the differentiation of several leukemia cell lines into monocytes, in particular, in combination with differentiation-inducing reagents. On the other hand, a dominant-negative form of TSC-22 accelerated the growth of Flt3-TKD-transduced 32Dcl.3 cells. Collectively, these results suggest that TSC-22 is a possible target of leukemia therapy.
UR - http://www.scopus.com/inward/record.url?scp=35548974356&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35548974356&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2404883
DO - 10.1038/sj.leu.2404883
M3 - Article
C2 - 17690703
AN - SCOPUS:35548974356
SN - 0887-6924
VL - 21
SP - 2246
EP - 2257
JO - Leukemia
JF - Leukemia
IS - 11
ER -